Hoechst Pakistan Ltd.

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: PK0021801011
PKR
3,444.54
231.54 (7.21%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Hoechst Pakistan Ltd. stock-summary
stock-summary
Hoechst Pakistan Ltd.
Pharmaceuticals & Biotechnology
Sanofi-Aventis Pakistan Limited (Sanofi) is a Pakistan-based company, which is engaged in the manufacturing and selling of pharmaceutical and consumer products. The Company's segment is manufacturing and selling of pharmaceutical and consumer products. The Company offers medicines, consumer healthcare products, generics and animal health products. Its products include oral anti-diabetics, such as Amaryl and Amaryl M, Daonil and Daonil - M, and Neodipar; insulins, such as Lantus, Apidra and SoloSTAR; cancer, such as Jevtana, Taxotere, Eloxatin and Fludara; pain management, such as No-Spa, Gardan, Muscoril and Profenid; allergy management, such as Telfast, Avil, Nasacort, Phenergan and Avomine; cough and cold, such as Rhinathiol and Tixylix; sleep disorders, such as Stilnox; emergency care, such as Haemaccel; cardiology, such as Plavix, CoPlavix, Aprovel, Co Aprovel, Clexane, Tritace, Co Tritacem and Winstor, and antibiotics, such as Tarivid, Claforan, Aventriax and Rulid.
Company Coordinates stock-summary
Company Details
Plot No. 23, Sector No. 22, Korangi Industrial Area, KARACHI None : 74900
stock-summary
Tel: 92 21 35060221
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summary Board of Directorsstock-summary
Management
Designation
Syed Babar Ali
Chairman, Independent Non-Executive Director
Mr. Yasser Pirmuhammad
Chief Financial Officer, Director
Amanullah Khan
Executive Director, Director Medical / APH
Ms. Naira Adamyan
Director
Dr. Pius Hornstein
Director
Mr. Shakeel Mapara
Director
Francois Briens
Non-Executive Director
Jean-Marc Georges
Non-Executive Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
8,720 Million
(Quarterly Results - Jun 2025)
Net Profit:
790 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

PKR 42,560 Million (Mid Cap)

stock-summary
P/E

17.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

2.50%

stock-summary
Debt Equity

-0.34

stock-summary
Return on Equity

38.26%

stock-summary
Price to Book

5.69